ÂÜÀòÂÒÂ×

Dr. Evren Alici is a senior researcher and group leader in Hematology at Karolinska Institutet (KI), Department of Medicine in Stockholm, Sweden where he leads a group of more than 20 scientists. He also serves as co-director of KI’s NextGenNK, an international competence center for the development of next-generation NK cell-based cancer immunotherapies. He received his M.D. and residency training at the Ege University, Turkey followed by a Ph.D. at KI.

He is a member of several international and national committees and advisory boards and is the Chairman and CEO of Vycellix. Dr. Alici participated in the planning and design of the first clinical study with gene-modified cells in Sweden and authored the final publication. He was also responsible for the first autologous NK cell clinical trial that was classified as advanced therapy medicinal product use.